Fractyl Health (GUTS) Gains from Investment Securities (2023 - 2026)
Fractyl Health (GUTS) reported Gains from Investment Securities of $123000.0 for Q1 2026, down 94.17% year-on-year from $2.1 million in Q1 2025, and up 100.75% quarter-over-quarter from -$16.4 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Gains from Investment Securities data on file, last reported at $123000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 94.17% year-over-year to $123000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.4 million (down 259.74% YoY), and the FY2025 full-year result was $3.2 million, down 68.53% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $123000.0, up from -$16.4 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $17.6 million in Q4 2024 and bottomed at -$16.4 million in Q4 2025.
- A 4-year average of $390122.7 and a median of $129000.0 in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities slumped 3745.74% in 2024 and jumped 211199.1% in 2025, its largest moves.
- Tracing GUTS's Gains from Investment Securities over 4 years: stood at -$1.2 million in 2023, then jumped by 1630.3% to $17.6 million in 2024, then tumbled by 193.15% to -$16.4 million in 2025, then jumped by 100.75% to $123000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $123000.0, -$16.4 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123,000.00 |
| Mar 31, 2026 | 123,000.00 |
| Dec 31, 2025 | -16.42 Mn |
| Dec 31, 2025 | -16.42 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 17.63 Mn |
| Dec 31, 2024 | 17.63 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | -4.70 Mn |
| Jun 30, 2024 | -4.70 Mn |
| Mar 31, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -1.15 Mn |
| Dec 31, 2023 | -1.15 Mn |
| Sep 30, 2023 | 1.03 Mn |
| Sep 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 129,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Mar 31, 2023 | 5,000.00 |